LONDON (Alliance News) - Physiomics PLC said Monday it has inked a new deal with an undisclosed pharmaceutical company for its Virtual Tumour product.
It said the project will be performed on a fee-for-service basis. No further financial details were disclosed.
"It is very pleasing that we have further extended the number of large pharmas starting to use Virtual Tumour. We look forward to adding more such customers as the benefits of our model are more widely understood," said Chief Executive Officer Mark Chadwick in a statement.
Shares in Physiomics were up 5.5% at 0.580 pence Monday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Physiomics (PYC)